Skip to content

Vascular-targeted photodynamic therapy (padeliporfin) for prostate cancer

How it works, the PCM301 trial, approval in Europe, side effects and what the guidelines say.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 18, 2026
Book a consultation
Drawing of the prostate in cross-section, seen from above, with light fibers inserted on one side and a reddish glow over the small blood vessels of the treated half
On this page

Quick answer

Vascular-targeted photodynamic therapy treats prostate cancer with a light-sensitive drug, padeliporfin, given into a vein and activated by a laser carried through fibers to the tumor area. The activated drug damages the blood vessels that feed the tumor.5 In the PCM301 trial, in men with low-risk cancer, the cancer progressed less with treatment than on active surveillance.3 The European guideline points out the limits of that trial and considers focal therapy for low-risk disease likely overtreatment.1

What it is and how it works

Vascular-targeted photodynamic therapy is one of the focal therapy techniques, which treat only the part of the prostate where the cancer is. The drug used is padeliporfin, a water-soluble chlorophyll derivative.9 In Europe, it was authorized under the name Tookad.5

On its own, padeliporfin does nothing. When it receives laser light, it produces large amounts of reactive oxygen molecules that damage the blood vessels feeding the tumor. Without that blood supply, the cancer cells die quickly.5

How it is done:3,5

  • The patient has general anesthesia.
  • The drug runs into a vein for about 10 minutes.
  • Thin light-carrying fibers are placed inside the prostate through hollow needles, in the area to be treated.
  • The laser light, with a wavelength of 753 nm in the PCM301 trial, stays on for just over 22 minutes.

In Europe, the treatment can only be given in hospital, by doctors trained in the technique.5

Who it is approved for

The European Medicines Agency (EMA) authorized padeliporfin in November 2017. The approved indication is narrow:5

  • Low-risk prostate cancer, on one side only and not previously treated
  • Clinical stage T1c or T2a, with Gleason 6 on biopsy (ISUP 1)
  • PSA of up to 10 ng/mL
  • Criteria on the number of cancer-containing cores and the tumor length in each, or on PSA density
  • Life expectancy of at least 10 years

The agency also lists situations in which the drug should not be used, such as some previous prostate procedures, cholestasis (a problem with bile flow), a flare of inflammatory bowel disease and men who cannot have general anesthesia.5

The PCM301 trial

PCM301 is the main trial of the technique and was run at 47 centers in Europe. It randomized 413 men with low-risk cancer to photodynamic therapy or to active surveillance.3

OutcomePhotodynamic therapyActive surveillance
Cancer progression at 2 years28%58%3
Cancer-free biopsy at 2 years49%14%3
Surgery or radiotherapy by 2 years7%32%4
Surgery or radiotherapy by 4 years24%53%4
Gleason 7 or higher on the final biopsy16%41%4

In the trial, "progression" meant the cancer moving from low risk to intermediate or high risk on biopsy.3

The European guideline makes two caveats. Progression in the surveillance group, 58% in 2 years, was far higher than expected. And that group had neither a confirmatory biopsy nor MRI, which does not reflect active surveillance today.1

Outside PCM301, studies are smaller and have no comparison group. In a 3.5-year follow-up of the phase 2 studies, with 68 men, the treated side was cancer-free in 75%, and 25% had cancer on the untreated side.6 In a French series of 82 men followed for about five and a half years, 76% avoided surgery or radiotherapy.7

Side effects

According to the European Medicines Agency, the most common side effects occur in up to 1 in 4 men:5

  • Difficulty passing urine, pain, urgency, frequent urination, urine leakage or retention
  • Erection and ejaculation problems
  • Blood in the urine and urinary infection
  • Pain and bleeding in the genital area

Most come from placing the fibers, are mild and settle within a few days.5 In PCM301, the most common severe side effects were prostatitis, acute urinary retention and erectile dysfunction, each in about 1% to 2% of treated men. Urinary retention was the most frequent serious side effect, in 15 men, and resolved within 2 months in all of them.3

If the cancer comes back

Because focal therapy leaves part of the prostate in place, cancer can come back on the treated side or appear on the other side.6 That is why follow-up with PSA, MRI and biopsy continues after treatment.

In a series from 14 European centers, 45 men had a prostatectomy for cancer that came back after photodynamic therapy. Surgeons rated the operation easy in 69% of cases, nerve sparing was possible in 33%, and the margin was positive in 31%.8 The European Medicines Agency says the effect of the therapy on later treatments is not yet clear.5 The robotic radical prostatectomy page explains the operation.

What the guidelines say

GuidelineWhat it says
European (EAU, 2026)For low risk, focal therapy is likely overtreatment and should not be used outside trials. For intermediate risk, offer focal therapy only within clinical trials or registries (strong recommendation)1
American (AUA/ASTRO, 2026)Tell patients with low- or intermediate-risk cancer that focal therapy remains investigational, without high-quality data comparing it with standard treatments2

The European guideline cites a review of 72 focal therapy studies with 5,827 men that favors HIFU and photodynamic therapy because their data are of higher quality than those of other energies.1 Even so, the only randomized trial of photodynamic therapy was done in very-low-risk men, exactly the group for whom the guidelines recommend active surveillance.1

When a second opinion helps

If you have been offered photodynamic therapy or are researching it, it is worth talking to another specialist:

  • If your cancer is low risk and active surveillance has not been discussed
  • If the diagnosis was made without an MRI or a targeted biopsy
  • If you want to compare focal therapy with surgery and radiotherapy
  • If your PSA or MRI has changed after focal therapy

A second opinion can be done entirely online, in English, with your test results sent in advance. The surgery or radiotherapy page helps compare whole-gland treatments.

Send your case

If you are having your prostate checked, with a raised PSA, an MRI or a biopsy, or you have already been diagnosed and would like my opinion before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

What is vascular-targeted photodynamic therapy?

It is a focal therapy that uses a light-sensitive drug, padeliporfin. It is given into a vein and only acts when it receives laser light carried by thin fibers to the treated area of the prostate. Once activated, the drug damages the blood vessels that feed the tumor, and the cancer cells die.5

How is photodynamic therapy of the prostate done?

Under general anesthesia. The drug runs into a vein for about 10 minutes, and light fibers are placed in the prostate through hollow needles.5 In the PCM301 trial, the laser light stayed on for just over 22 minutes.3

Who is photodynamic therapy approved for?

The European Medicines Agency approved padeliporfin in 2017 for men with low-risk prostate cancer on one side only, with no previous treatment, Gleason 6, a PSA of up to 10 ng/mL and a life expectancy of at least 10 years, plus criteria on the size of the tumor on the biopsy.5

What did the PCM301 trial show?

It randomized 413 men with low-risk cancer to photodynamic therapy or active surveillance. At 2 years, the cancer progressed in 28% of treated men and in 58% of men on surveillance.3 At 4 years, 24% of treated men and 53% of monitored men had had surgery or radiotherapy.4 The European guideline points out that surveillance in the trial did not follow today's standard, with no MRI.1

What are the side effects of photodynamic therapy?

The most common, in up to 1 in 4 men, are urinary problems, erection and ejaculation problems, blood in the urine, urinary infection and pain in the genital area. Most come from placing the fibers and settle within a few days.5 In PCM301, the most frequent serious side effect was urinary retention, which resolved within 2 months.3

Can I have surgery after photodynamic therapy?

In a European series of men who needed a prostatectomy after treatment, surgeons rated the operation easy in 69% of cases, and nerve sparing was possible in 33%.8 The European Medicines Agency says the effect of the therapy on later treatments is not yet clear.5

What do the guidelines say about photodynamic therapy?

The European guideline considers focal therapy for low-risk disease likely overtreatment that should not be used outside trials, and recommends active surveillance.1 The American guideline says focal therapy remains investigational for low- and intermediate-risk disease.2

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  2. Eastham JA, Barocas DA, Chu CE, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026). J Urol. 2026;216(1):2-11. PubMed
  3. Azzouzi AR, Vincendeau S, Barret E, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(2):181-191. PubMed
  4. Gill IS, Azzouzi AR, Emberton M, et al. Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness. J Urol. 2018;200(4):786-793. PubMed
  5. European Medicines Agency. Tookad (padeliporfin): EPAR summary and authorised indication. Updated 20/10/2026. EMA
  6. Noweski A, Roosen A, Lebdai S, et al. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). Eur Urol Focus. 2019;5(6):1022-1028. PubMed
  7. Lebdai S, Bigot P, Leroux PA, et al. Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes. J Urol. 2017;198(2):335-344. PubMed
  8. Pierrard V, Lebdai S, Kleinclauss F, et al. Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results. J Urol. 2019;201(2):315-321. PubMed
  9. Nogueira L, Tracey AT, Alvim R, et al. Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies. Molecules. 2020;25(22):5417. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides